Cannabinoid Type 1 Receptor Antagonism Delays Ascites Formation in Rats With Cirrhosis

Gastroenterology

Volumn 137, Issue 1, 2009, Pages 341-349

  Domenicali, Marco ^a,b   Caraceni, Paolo ^a,b   Giannone, Ferdinando ^a,b   Pertosa, Anna Maria ^a,b   Principe, Alessandro ^a,b   Zambruni, Andrea ^a   Trevisani, Franco ^a   Croci, Tiziano ^c   Bernardi, Mauro ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Exploratory Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; RIMONABANT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; HEART OUTPUT; HEMODYNAMICS; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM BALANCE; SODIUM INTAKE; SODIUM RETENTION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR RESISTANCE;

EID: 67449166655     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.004     Document Type: Article

References (30)

1. Pacher P., Bátkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
2. Liu J., Gao B., Mirshahi F., et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 (2000) 835-840
3. Bonz A., Laser M., Küllmer S., et al. Cannabinoids acting on CB1-receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41 (2003) 657-664
4. Mackie K., and Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8 (2006) E298-E306
5. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12 (2006) 671-676
6. Bátkai S., Járai Z., Wagner J.A., et al. Endocannabinoids acting at vascular CB1-receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7 (2001) 827-832
7. Ros J., Claria J., To-Figueras J., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122 (2002) 85-93
8. Domenicali M., Ros J., Fernández-Varo G., et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 54 (2005) 522-527
9. Blei A.T. Portal hypertension and its complications. Curr Opin Gastroenterol 23 (2007) 275-282
10. Iwakiri Y., and Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 Suppl 1 (2006) S121-S131
11. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
12. Jiménez W., Martinez-Pardo A., Arroyo V., et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 5 (1985) 245-250
13. 4-induced cirrhosis. J Hepatol 43 (2005) 92-97
14. Jiménez W., Cària J., Arroyo V., et al. Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 7 (1992) 90-97
15. Welch W.J., Deng X., Snellen H., et al. Validation of miniature transit-time probes for measurement of renal blood flow in rats. Am J Physiol 268 (1995) F175-F178
16. rd ed. (1999), Butterworth Heinemann, Oxford, England
17. Chieco P., Jonker A., and Van Noorden C.J.F. Image cytometry (2001), BIOS Scientific, Oxford, England
18. Brugghe J., Baak J.P.A., Meijer G.A., et al. Rapid and reliable assessment of volume percentage of epithelium in borderline and invasive ovarian tumors. Anal Quant Histol Cytol 20 (1997) 14-20
19. Rinaldi-Carmona M., Barth F., Héaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
20. Pagotto U., Marsicano G., Cota D., et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
21. Colombo G., Agabio R., Diaz G., et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63 (1998) 113-117
22. Bernardi M., and Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Schrier R.W., Arroyo V., and Rodés J. (Eds). The liver and the kidney (2005), Blackwell Scientific, Malden, MA 43-53
23. Bernardi M. Renal sodium retention in pre-ascitic cirrhosis: expanding knowledge, enduring uncertainties. Hepatology 35 (2002) 1544-1547
24. Pizcueta P., Piqué J.M., Fernández M., et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 103 (1992) 1909-1915
25. Moezi L., Gaskari S.A., Liu H., et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 149 (2006) 898-908
26. Gaskari S.E., Liu H., Moezi L., et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomiopathy in bile duct-ligated rats. Br J Pharmacol 146 (2005) 315-323
27. Batkai S., Mukhopadhyay P., Harvey-White J., et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 293 (2007) H1689-H1695
28. Koura Y., Ichihara A., Tada Y., et al. Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. J Am Soc Nephrol 15 (2004) 1488-1494
29. Li J.L., and Wang D.H. Differential mechanisms mediating depressor and diuretic effects of anandamide. J Hypertens 24 (2006) 2271-2276
30. Janiak P., Poirer B., Bidouard J.P., et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72 (2007) 1345-1357